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DEVELOPMENT OF AN MHC-PEPTIDE ARRAY FOR THE DETECTION
AND ISOLATION OF ANTIGEN-SPECIFIC T-CELLS: APPLICATIONS IN
BONE MARROW TRANSPLANTATION FOR EVALUATION OF T-CELL RE-
CONSTITUTION, AND DETECTION OF HOST REACTIVE AND TUMOR-
REACTIVE T-CELLS
Kraft, D.L., Soen, Y., Chen, D.S., Weissman, I.L., Brown, P.O., Davis,
M.M. Stanford University School of Medicine, Stanford, CA
Identiﬁcation and characterization of antigen-speciﬁc T cell pop-
ulations is critical for the detection and analysis of immune re-
sponses, particularly following bone marrow and hematopoietic
stem cell (HSC) transplantation. Current MHC-peptide tetramer
methodology, which relies on ﬂow cytometry, is technically difﬁ-
cult and most often limited to analysis of one or two peptide-
speciﬁc T cell populations at a time. We have developed an array-
based strategy, which allows rapid, simultaneous identiﬁcation,
isolation and characterization of multiple antigen-speciﬁc popula-
tions of T cells. MHC-peptide complexes were robotically arrayed
in triplicate in 400um diameter spots onto polyacrylamide ﬁlm-
coated glass slides. CD4 and/or CD8 lymphocytes are immo-
bilized on the array of pre-printed MHC-peptide complexes in an
antigen-speciﬁc fashion. Speciﬁcity and limit of detection of anti-
gen-speciﬁc T-cells down to 0.1 % were determined using differ-
entially labeled lymphocytes from TCR-transgenic mice and vali-
dated by detection of a rare population of post-vaccination
antigen-speciﬁc T cells in a wild type mouse. We also have devel-
oped a simple solution for screening large libraries of MHC-
restricted epitopes using reloadable MHC-peptide constructs.
This approach should be useful for epitope discovery, and simul-
taneous analysis of multiple epitope-speciﬁc T cell populations
during natural and induced immune responses associated with
cancer, microbial infection, and autoimmunity. Applications of this
novel technology in marrow and stem cell transplantation include
the detection of epitope-speciﬁc T-cells within both the donor
graft, as well as a means to quantify donor derived, antigen-speciﬁc
T-cell reconstitution against a large library of target MHC/peptide
epitopes. Utilizing an array, we have demonstrated detection of
antigen speciﬁc T-cells following TCR-transgenic HSC transplan-
tation. Use of MHC/peptide arrays may be of utility in detecting
and monitoring T-cell populations responsible for Graft vs Leu-
kemia and Graft vs Host Disease. Additionally, antigen-speciﬁc
T-cells can be removed from the array and expanded, or their
TCR-cloned for potential follow-on immunotherapy.
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THE IMPACT OF IMMUNE RECONSTITUTION IN THE EARLY POST
GRAFTING PERIOD ON THE DEVELOPMENT OF OPPORTUNISTIC IN-
FECTIONS AFTER UNRELATED CORD BLOOD TRANSPLANTATION. A
MULTIVARIATE ANALYSIS OF HOST, GRAFT, AND DAY 50 IMMUNE
PROFILE
Szabolcs, P., Park, K.D., Marti, L., Reese, M., Lee, Y.A., Oliveira,
D.D., Sanders, L., Niedzwiecki, D., Kutzberg, J. Duke University
Medical Center, Durham, NC
Unrelated umbilical cord blood transplantation (uUCBT) is a
suitable option for those who lack HLA-matched sibling donors.
However, opportunistic infections (OI), most occurring in the ﬁrst
100 days, remain the major cause of morbidity and mortality. Here
we report on 102 pediatric patients, all full donor chimera, pro-
spectively studied to identify those who are at increased risk for
developing OI. Methods: On day 50 we determined by 4-color
surface and intracellular FACS the reconstitution of T cell subsets
(e.g.: recent thymic emmigrants [RTE]), naive, memory, CTL),
lymphoid, and myeloid dendritic cells (DC), besides proliferation
and cytokine secretion. We analyzed their association with the
development of de novo OI up to day 120. Logistic regression
models were created for those variables that had a P value of0.05.
Results: Mean age of patients was 6.3 years, 66 of the 102 patients
are alive at a mean time of 749 days post-transplant. The median
time for death was D95. 53 patients (52%) developed OI, mostly
viral etiology (adeno, CMV, HHV-6, parainﬂuenza, HSV, poly-
oma). Survival was lower in patients who developed OI (47% vs
82%, p  0.0001). Of the potential confounders younger age,
higher infused total cells/kg, and CD3 T cells/kg correlated with
absent OI (p  0.0007). The dose of CD34 cells/kg, gender,
steroid pulse did not correlate with OI. Patients with aGVHD
grade III-IV had increased incidence of OI just as those who were
mismatched at 2 or 3 HLA loci compared with 0 or 1 (p  0.009).
Table 1 presents variables of day 50 immunity and their statis-
tical correlation with OI. Additionally, in a recent subset of patients
(n  12) effectors of cytotoxicity were analyzed. More T cells
expressed Granzymes A, B, and Perforin in those who experienced
OI (50% vs 10%, p  0.04). CD8 T cell skewing, “Suppres-
sor” T cells, “NKT” cells, HLA-DRT cell subsets along with
IFN secretion appeared only in those infected patients who had
developed OI before the lab studies and are the consequence/
correlate of OI. True predictors of OI were identiﬁed by compar-
ing those who had immune parameters tested before the onset of
OI (n  37) with those who lacked OI (n  49). Higher absolute
numbers of lymphoid DC, T cells, CD4T cells were found to be
protective from OI (p 0.03). Conclusion: We conclude from the
largest prospectively analyzed cohort of uUCBT patients that
select features of early immune reconstitution may identify those at
risk for OI while others merely reﬂect it.
Table. Univariate and multivariate analysis of Day 50 immune
reconstitution with patient and graft-speciﬁc confounders
Variable
Median
Value
for
Patients
with OI
Median
Value
for
Patients
Without
OI
Rank
Sum
Test
P
Value
Logistic
Regression
P Value
CD3 T cells/L 88 177 0.03 NS
CD4 T cells/L 44 137 0.0001 NS
(because
of age)
% CD4 T cells 57% 86% 0.0001 <0.001
CD45RA/CD62
“RTE” cells/L
5 11 0.002
% CD57/CD28/
CD8
“suppressor” T
cells
8% 2% 0.003 <0.01
% CD25/CD3 22% 40% 0.005 <0.016
% TCR T cells 2% 1% 0.008 <0.033
% “naive”
CD45RA
15% 31% 0.002 NS
(because
of age)
/CD27/CD8 T
cells
% “activated”
HLA-DR T
cells
53% 38% 0.0002 <0.02
% “NKT” CD3/
CD56 T cells
7% 4% 0.003 <0.02
% IFN secreting
T cells
11% 4% 0.0004 <0.01
“lymphoid”
CD123 DC/L
0.9 2.7 0.009 NS
PHA (cpm) 10,600 51,400 0.005 NS
(because
of age)
Confounders tested; age, gender, weight, CMV status, HLA mismatch, malignancy, TBI,
GVHD, HD steroid pulse, Daclizumab pulse, infused total cell dose/kg, CD34 pro-
genitor/kg, CD3 T-cell dose/kg.
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